Načítá se...
Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
The recent introduction of direct-acting antiviral drugs (DAAs) for treatment of the hepatitis C virus (HCV) has greatly improved the management of HCV for infected patients. These viral protein inhibitors act rapidly, allowing HCV clearance and increasing the sustained virological response rates. H...
Uloženo v:
| Vydáno v: | World J Gastroenterol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Baishideng Publishing Group Inc
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5487495/ https://ncbi.nlm.nih.gov/pubmed/28706414 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v23.i24.4317 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|